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Abstract
Background: Receptor tyrosine kinases (RTK) are potential targets for the treatment of ischemic heart disease. The
human RTK family consists of 55 members, most of which have not yet been characterized for expression or activity
in the ischemic heart.
Methods: RTK gene expression was analyzed from human heart samples representing healthy tissue, acute
myocardial infarction or ischemic cardiomyopathy. As an experimental model, pig heart with ischemia-reperfusion
injury, caused by cardiopulmonary bypass, was used, from which phosphorylation status of RTKs was assessed with
a phospho-RTK array. Expression and function of one RTK, ROR1, was further validated in pig tissue samples, and in
HL-1 cardiomyocytes and H9c2 cardiomyoblasts, exposed to hypoxia and reoxygenation. ROR1 protein level was
analyzed by Western blotting. Cell viability after ROR1 siRNA knockdown or activation with Wnt-5a ligand was
assessed by MTT assays.
Results: In addition to previously characterized RTKs, a group of novel active and regulated RTKs was detected in
the ischemic heart. ROR1 was the most significantly upregulated RTK in human ischemic cardiomyopathy. However,
ROR1 phosphorylation was suppressed in the pig model of ischemia-reperfusion and ROR1 phosphorylation and
expression were down-regulated in HL-1 cardiomyocytes subjected to short-term hypoxia in vitro. ROR1 expression
in the pig heart was confirmed on protein and mRNA level. Functionally, ROR1 activity was associated with reduced
viability of HL-1 cardiomyocytes in both normoxia and during hypoxia-reoxygenation.
Conclusions: Several novel RTKs were found to be regulated in expression or activity in ischemic heart. ROR1 was
one of the most significantly regulated RTKs. The in vitro findings suggest a role for ROR1 as a potential target for
the treatment of ischemic heart injury.
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Background
Ischemic heart disease is the leading cause of death glo-
bally [1]. In the case of an acute myocardial infarction,
myocardial damage caused by ischemia is exacerbated by
oxygenized blood returning to the heart at reperfusion
[2]. Approaches to treat infarction should both promote
reperfusion and protect myocardium from the detrimen-
tal effects of ischemia and reperfusion.
Receptor tyrosine kinases (RTK) are cell surface receptors
that mediate cellular survival, proliferation, and migration.
A few RTKs have been shown to be necessary for develop-
ment of the heart in gene-modified mouse models. Such
examples include Erbb2 [3, 4], Erbb4 [5], Ror1 [6], and Ror2
[6, 7]. Understanding of the regulation of RTK activity and
expression in ischemic heart is limited to few receptors.
Expression of EGFR and ERBB2 have been demonstrated
to be regulated in infarcted human heart [8, 9], and alter-
ations in EGFR, ERBB2, ERBB4, VEGFR1, VEGFR2, IGF1R,
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and INSR signaling have been observed in experimental
ischemia-reperfusion models [8, 10–12].
Few RTKs have been investigated as targets for the treat-
ment of experimental ischemia-reperfusion injury. Induction
of constitutively active ERBB2 after infarction causes myocar-
dial regeneration in mice [13]. Activating ERBB4 with its lig-
and neuregulin-1 reduces scar size in mouse [14] and rat
[15] infarction models. Activation of INSR by insulin
infusion during reperfusion has been shown to reduce infarc-
tion size in an ischemia-reperfusion rat heart model in
Langendorff perfusion system [16]. Moreover, glucose-insu-
lin-potassium infusion has been tested in clinical trials as a
myocardial infarction treatment with mixed results [17].
Here, we used an in silico expression analysis and a phos-
phoarray analysis of an in vivo pig ischemia-reperfusion in-
jury model to screen for changes in the expression and
activity of RTKs in normal vs. ischemic heart. ROR1 was
identified as a receptor demonstrating activity in both
screens. We show that ROR1 was expressed in human heart,
in pig myocardium and in cultured mouse cardiomyocytes
and rat cardiomyoblasts. In cardiomyocytes in vitro, both
ROR1 expression and phosphorylation were downregulated
by hypoxia. We also demonstrate that ROR1 knockdown en-
hanced, and treatment with its ligand, Wnt-5a, reduced the
viability of cardiomyocytes. These findings suggest that
ROR1 signaling may suppress survival of cardiomyocytes
and that ROR1 could be further tested as a potential treat-
ment target for the myocardial ischemic injury.
Methods
In silico transcriptomics
Affymetrix gene expression data from IST Online data-
base (ist.medisapiens.com; Medisapiens Ltd.) were ana-
lyzed to characterize RTK expression in samples
representing healthy heart (n = 62), acute myocardial in-
farction (n = 12) or ischemic cardiomyopathy (n = 63).
Out of the 55 RTKs listed by HUGO Gene Nomencla-
ture Committee, data were available for 49 genes in
acute myocardial infarction samples and for 52 genes in
ischemic cardiomyopathy samples (Additional file 1).
Data were normalized by array-generation-based gene
centering method [18] and log2-transformed. Expression
levels of RTKs demonstrating statistically significant dif-
ferences in two-group comparisons were visualized as
box plots and heatmaps using Pretty Heatmaps package
(pheatmap) [19] in RStudio [20].
Pig model of heart ischemia-reperfusion injury
Animal experiments were approved by the Laboratory
Animal Care and Use Committee of the State Provincial
Office of Southern Finland (license number: ESAVI/
1167/04.10.03/2011). The landrace pig myocardial sam-
ples (n = 7) were a kind gift from Drs. Christoffer Stark
and Timo Savunen. Experimental procedure has been
described in detail earlier [21]. Pigs weighed 29–43 kg.
Myocardial ischemia-reperfusion injury was produced by
exposing anesthetized pigs (n = 4) to cardiopulmonary
bypass with aortic cross-clamping and cardioplegic ar-
rest for 60 min, causing global myocardial ischemia. A
pediatric membrane oxygenator (Dideco 905 Eos,
Dideco) was used for the bypass. Procedures were per-
formed in the laboratory of Research Center of Applied
and Preventive Cardiovascular Medicine, University of
Turku, Turku, Finland. For pre-anesthesia, an intramus-
cular injection of 100 mg xylazin (Rompun vet, Bayer
Animal Health GmbH) and 25 mg midazolam (Midazo-
lam Hameln, Hameln pharmaceuticals GmbH) was used.
For anesthesia, 20 mg boluses of propofol (PropofolLi-
puro, B. Braun Melsungen AG) and 150 μg phentanyl
(Fentanyl-Hameln, Hameln pharmaceuticals GmbH)
were administered via a cannulated ear vein, and pigs
were intubated and connected to a respirator (Dräger
Oxylog 3000, Drägerwerk AG), the respiratory rate set
to 18–22 times/min with a tidal volume of 8–10 ml/kg
using 40% oxygen. Continuous infusion of propofol 15–
30 mg/kg/h, phentanyl 1.5 μg/kg/h and midazolam
100 μg/kg/h was used to maintain anesthesia. A right
sided thoracotomy was performed and the ascending
aorta and right atrium cannulated for the bypass. 500 ml
of cold (10 °C) Modified St Thomas Hospital No II car-
dioplegia was used to protect the hearts during the by-
pass, administered via a cannula to the aortic root at the
time of cross-clamping and 30 min later. Antibiotic
prophylaxis (Cefuroxime 750 mg, Orion Pharma) was
given preoperatively and then every 8 h. 10,000 IU of
heparin (Heparin, LEO Pharma) was administered as a
bolus before cannulation of the heart and this was re-
peated every 30 min during extracorporeal circulation.
14,000 IU of protamine sulphate (Protamin, LEO
Pharma) was used to neutralize the heparin. For throm-
bosis prophylaxis, 20 mg of enoxaparin (Klexane, Sanofi)
was administered 1 and 12 h after the surgery. 100–
150 mg of lidocaine (Lidocain, Orion Pharmaceuticals)
and 150–225 mg of amiodarone (Cordarone, Sanofi)
were used for rhythm disorders, and 5 mg boluses of
ephedrine (Efedrin, Stragen Nordic) and noradrenaline
infusion (80–160 μg/h) (Noradrenalin Hospira, Hospira)
were used for post-operative hemodynamic support,
when needed. For post-operative analgesia, 50 mg of
bupivacaine (Bicain, Orion Pharmaceuticals) was infiltrated
to the wound. For monitoring of adequate ventilation and
perfusion, blood gases (i-STAT, Abbott Laboratories), inva-
sive central venous pressure, ECG and oxygen saturation
were followed throughout the procedure.
After the 60-min aortic cross-clamping, hearts were
reperfused and the pigs were maintained anesthetized
and mechanically ventilated for 29–31 h before sacrifica-
tion with intravenous injection of potassium chloride.
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Control samples (n = 3) were obtained from pigs used as
blood donors for priming of the heart-lung machine.
The control pigs underwent the same anesthetic protocol as
the treatment group. Transmural left ventricle samples, col-
lected after the sacrification, were snap-frozen and stored at
− 80 °C. Troponin T levels were measured from plasma sam-
ples of ischemia-reperfusion-injured pigs, collected at the
baseline and 6 and 24 h after reperfusion, by the laboratory
of the Turku University Central Hospital using electrochemi-
luminescence immunoassay (Elecsys Troponin T high sensi-
tive, Roche). Formalin-fixed, paraffin-embedded tissue
samples were stained with hematoxylin and eosin and im-
aged with Zeiss AxioImager M1 microscope.
Phosphoarray analysis of RTK phosphorylation
Pig myocardial samples (280 to 460 mg) were homoge-
nized and analyzed for phosphorylation status of 49
RTKs using the Proteome Profiler Human Phospho-RTK
Array Kit (R&D Systems). Five hundred μg of protein
was analyzed per sample. Receptors included in the ana-
lysis are listed in Additional file 2 B.
Array blot images were quantified by densitometry
with NIH ImageJ v1.50i software. Intensity values were
normalized by dividing each dot’s intensity with the sum
of intensities of the whole array, allowing comparison
between different samples. Data were scaled to interval
0–1 by dividing all values with the highest value. Nor-
malized values were visualized as a bargraph (mean
(SD)) and as a heatmap with Pretty Heatmaps package
[19]. Receptors with at least two quantifiable results in
both sample groups were included. Receptors were clus-
tered using maximum distance method.
Cell culture and Wnt-5a ligand treatment
HL-1 mouse atrial cardiomyocytes were a kind gift from
Dr. Pasi Tavi (University of Eastern Finland). HL-1 cells
were maintained in Claycomb medium (Sigma) supple-
mented with 10% FBS, 0.1 mM norepinephrine, 50 U/ml
penicillin, 50 U/ml streptomycin, and 2 mM UltraGluta-
mine (Lonza). Culture plates were coated at 37 °C with a
solution containing 0.02% gelatin and 10 μg/ml fibronec-
tin. Seeding densities were 140,000 cells/6-well plate
well, 100,000 cells/12-well plate well, and 5,000 cells/
96-well plate well. H9c2 rat cardiomyoblasts were pur-
chased from ATCC and maintained in DMEM with
1.5 g/l NaHCO3, supplemented with 10% FBS, 50 U/ml
penicillin, 50 U/ml streptomycin, and 2 mM UltraGluta-
mine. Seeding density was 100,000 cells/6-well plate
well. Cells were routinely checked for mycoplasma infec-
tion using MycoAlert Mycoplasma Detection Kit
(Lonza). For hypoxia-reoxygenation experiments, the
cells were cultured in 1% O2 in a hypoxic work station
(InVivo2, Ruskinn Technology Ltd.) for the indicated pe-
riods of time, and returned to normal cell incubator
(21% O2) for reoxygenation. In ROR1 ligand activation
experiments, 200–400 ng/ml of recombinant human/
mouse Wnt-5a (R&D Systems) was added to medium at
the time of plating (for MTT assays) or 24 h after plating
for 30–60 min (for Western analyses).
RNA interference
One day after plating, HL-1 cells were transfected with siR-
NAs (Qiagen) targeting ROR1 (siRNA #1, SI01404655;
siRNA #2, SI01404662), or ROR2 (siRNA #1, SI01404683;
siRNA #2, SI01404690) or with AllStars Negative Control
siRNA at a concentration of 100 nM, using Lipofectamine
2000 (Invitrogen). Immediately prior to transfection, medium
was changed to antibiotic- and norepinephrine-free
Claycomb medium. Four to six hours after transfection,
medium was replaced with antibiotic-free, norepinephrine-
supplemented Claycomb medium.
RNA extraction and real-time RT-PCR
RNA was extracted from pig myocardium samples using
TRIsure reagent (Bioline). Samples were treated with
10 units of DNAse I (Roche). cDNA was synthesized
with SensiFAST cDNA Synthesis Kit (Bioline), using
1 μg of total RNA/sample. Real-time RT-PCR was car-
ried out using QuantStudio 12 K Flex Real-Time PCR
System thermal cycler (Thermo Fisher Scientific). For
PCR reactions, 5 μl of TaqMan Universal Master Mix II
(Thermo Fisher Scientific) and 10 ng of template cDNA
were used in a reaction volume of 10 μl. Primer concen-
trations were 0.3 μM and probe concentration 0.1 μM.
Primers were acquired from Eurofins Genomics and
probes from Universal Probe Library (Roche). GAPDH
was used as the reference gene [8]. ROR1 was analyzed
using the primers 5’-GCGGCTCGCAATATTCTC-3′
and 5’-GAAAGCCCAAGGTCTGAAATC-3′, and the
probe #108. GAPDH was analyzed using the primers
5’-ACAGACAGCCGTGTGTTCC-3′ and 5’-ACCTTCACC
ATCGTGTCTCA-3′, and the probe #28.
Western blotting and immunoprecipitation
Cells were lysed with lysis buffer [22] supplemented with
Pierce Protease Inhibitor Mini Tablets (Thermo Fisher
Scientific). Lysates were centrifuged for 15 min at 16,000 g
and the supernatants were collected. Snap-frozen pig
heart tissue samples were dissolved in ice-cold Lysis Buffer
17 supplied with the Proteome Profiler Human
Phospho-RTK Array Kit. Samples were separated on 8–
10% polyacrylamide gels. Protein amounts loaded on the
gel were 20–35 μg for cell samples and 100 μg for pig tis-
sue samples. Separated samples were transferred to nitro-
cellulose membrane which was blocked with 5% non-fat
milk or bovine serum albumin in 10 mM Tris-HCl
(pH 7.4), 150 mM NaCl and 0.05% Tween-20 (blocking
solution) for 1 h at room temperature. Membranes were
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incubated with primary antibodies overnight at 4 °C in the
blocking solution. The following primary antibodies and
dilutions were used: anti-ROR1 (sc-83033 and sc-130386,
Santa Cruz Biotechnology; 1:250 and 1:125, respectively),
anti-actin (sc-1616, Santa Cruz Biotechnology; 1:1,000),
anti-α-tubulin (sc-5546, Santa Cruz Biotechnology; 1:1,000),
anti-phospho-Akt (#4060, Cell Signaling Technology;
1:1,000), anti-Akt (#9272, Cell Signaling Technology;
1:1,000), anti-phospho-p38 (#9211, Cell Signaling Technol-
ogy; 1:500), anti-p38 (#9212, Cell Signaling Technology;
1:500), anti-phospho-tyrosine (4 g10, Upstate; 1:500), and
anti-GAPDH (G8795, Sigma-Aldrich; 1:1,000). Incubation
with secondary HRP-conjugated antibodies (Santa Cruz Bio-
technology; 1:5,000) or IRDye secondary antibodies (LI-COR,
1:10,000) was carried out for 1 h at room temperature in the
blocking solution. The immunosignals were visualized with
WesternBright ECL HRP substrate reagent (Advansta) and
imaged with ImageQuant LAS 4000 (GE Healthcare Life Sci-
ences) or with Odyssey imaging system (LI-COR). Densito-
metric analysis of the Western signals was carried out with
ImageJ.
For immunoprecipitation analyses, approximately
2 mg of total protein from HL-1 cell lysates was incu-
bated overnight at 4 °C with 4 μg of mouse monoclonal
anti-ROR1 antibody (sc-130386, Santa Cruz Biotechnol-
ogy). Immunoprecipitated lysates were incubated with
Protein G PLUS-Agarose beads (sc-2002, Santa Cruz
Biotechnology) for one hour at 4 °C. After washing the
beads three times with lysis buffer without protease in-
hibitors, samples from the supernatants were loaded
onto 10% polyacrylamide gels for subsequent Western
analysis.
MTT cell viability assay
CellTiter 96 Non-Radioactive Cell Proliferation Assay
(MTT) (Promega) was used to measure viability of HL-1
cells. The assay was performed on 96-well plates with plat-
ing density of 5,000 cells/well. Before addition of the MTT
dye solution, the culture medium was replaced by
norepinephrine-free Claycomb medium (100 μl/well).
Wells only containing the medium were used for back-
ground subtraction. Absorbances at 570 nm were detected
with EnSight Multimode Plate Reader (PerkinElmer) and
results were normalized to untreated control sample level.
Protein sequence alignment
Human and pig RTK protein sequences from UniProt
database were aligned using EMBOSS Needle tool for
global alignments and EMBOSS Water tool for local
alignments by the European Bioinformatics Institute
(http://www.ebi.ac.uk/Tools/psa/) [23]. The longest pig
sequences available were used.
Statistical analyses
For in silico transcriptomics analyses, Student’s t-test
was used to assess the significance of differences be-
tween the expression levels of an RTK between sample
groups. Correction for multiple testing was performed
using false discovery rate (FDR) method [24]. Genes with
significant differences in expression were selected for vi-
sualizations. Two-tailed Student’s t-test was used for
testing the significance of differences in phosphorylation
array data (for RTKs with at least three quantifiable re-
sults in both treatments) and in expression levels in
Western analyses. For in vitro experiments, data are rep-
resented as box plots depicting median (black horizontal
line), first and third quartile (box) and the range of the
data (whiskers). Multiple group comparisons were per-
formed with Kruskal-Wallis test with Dunn’s post-hoc
test using FDR method for P-value adjustments. P-values
< 0.05 were considered significant. Analyses were per-
formed with RStudio.
Results
Regulation of RTK expression in ischemic human heart
Expression of human RTKs in healthy heart, heart with is-
chemic cardiomyopathy and heart with acute myocardial in-
farction was analyzed in silico using the IST Online
database. Comparison of healthy samples to ischemic cardi-
opathy samples revealed a set of 14 receptors that were sig-
nificantly differently expressed at the mRNA level (Fig. 1a).
The most significantly up- and downregulated RTKs were
ROR1 and EPHA2, respectively, when ischemic cardiomyop-
athy was compared to normal heart (Fig. 1b). Interestingly,
another ROR family member, ROR2, was downregulated in
the ischemic cardiomyopathy samples (Fig. 1a). When com-
paring healthy hearts with hearts representing acute myocar-
dial infarction, significant downregulation of EGFR, ERBB2,
ERBB3, as well as EPHA2, was discovered in the infarcted
heart, ERBB2 demonstrating the greatest difference in ex-
pression (Fig. 1c and d). Statistical test values and differences
in expression are shown in Additional file 1 and heatmaps
generated from the data in Additional file 3.
RTK phosphorylation in experimental pig ischemia-
reperfusion model
To experimentally address RTK activation in the ischemic
heart, an ischemia-reperfusion model in pig, a relevant
model animal close to human as a large mammal, was used.
Pigs were subjected to ischemia-reperfusion injury by car-
diopulmonary bypass and reperfusion, followed by
phospho-RTK array analysis of myocardial samples. In-
creased amount of troponin T in the plasma (Additional file
4 A) and thinned cardiomyocytes with condensed nuclei as
demonstrated by histological analysis (Additional file 4 B)
indicated ischemic injury. The phosphoarray analysis was
carried out after approximately 30 h of reperfusion. While
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the observed phosphorylation-specific signal was relatively
weak (possibly due to loss of phosphosignal during sample
preparation and/or low cross-reactivity of the array
antibodies between human and pig epitopes) (Additional
file 2 A), the data indicated the presence of 23 activated




Fig. 1 Regulation of RTK expression in acute myocardial infarction and ischemic cardiomyopathy. Messenger RNA expression of 52 RTKs in
human tissue samples representing healthy heart (n = 62), ischemic cardiomyopathy (n = 63), or acute myocardial infarction (n = 12) was analyzed
in silico using IST Online database. a A dotplot presentation of FDR-corrected P values vs. the fold changes of RTK expression levels between
samples representing ischemic cardiomyopathy or healthy heart. b A box plot presentation of expression levels of the most significantly up- or
downregulated RTKs in ischemic cardiomyopathy vs. healthy heart. c A dotplot presentation of FDR-corrected P values vs. the fold changes of
RTK expression levels between samples representing acute myocardial infarction or healthy heart. d A box plot presentation of expression level of
the most significantly downregulated RTK in acute myocardial infarction vs. healthy heart. In A and C, the fold changes of means were calculated
from log2-transformed Affymetrix expression values (arbitrary units). Vertical grey lines depict the threshold P = 0.05. RTKs not demonstrating
significant (P < 0.05) changes in expression are only depicted by dots without labels
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about RTK activity in the heart [8–12], the array identified
phosphorylated EGFR, INSR, VEGFR2, and ERBB2 in both
ischemic (n = 4) and control samples (n = 3) (Fig. 2a). Phos-
phorylation of a group of receptors, that to our knowledge
have not previously been shown to be active or regulated in
ischemic heart, was also detected. This group included both
ROR receptors ROR1 and ROR2; the EPH receptors
EPHB2, EPHB3, EPHB6, and EPHA10; TYRO3; RYK;
FGFR3 and ALK (Fig. 2a).
Densitometric quantitation of the data indicated highest
activity for EGFR, ROR2, INSR, EPHB3, EPHB2, TEK,
TYRO3, RYK, ROR1 and EPHB6 (phosphosignal exceeding
the 75th percentile of mean phosphorylation levels of all
RTKs in all samples). Phosphorylation of ROR1 was sig-
nificantly downregulated (P = 0.022), and phosphoryl-
ation of VEGFR2 significantly upregulated (P = 0.043),
in ischemia-reperfusion-injured hearts. Unsupervised
clustering of the RTKs on a heatmap grouped highly
A
B
Fig. 2 RTK phosphorylation in a pig model of ischemia-reperfusion injury. A phospho-RTK array analysis addressing the phosphorylation of 49
RTKs was carried out for heart samples from a pig model of ischemia-reperfusion injury. Control pigs underwent the same anesthetic protocol as
the ischema-reperfusion-injured pigs. a The intensity of the dots in the phospho-array were quantified by densitometry and normalized to each
array’s sum of intensities. The resulting values were scaled according to the highest value set to one. Normalized phosphorylation values of each
receptor with at least two non-zero results per each treatment are shown (mean + SD). b The same set of normalized phospho-RTK dot
intensities were visualized as a heatmap. Receptors with at least two samples with non-zero results per each treatment were included, and were
clustered using the maximum distance method. White tiles depict missing data for few samples. Asterisk indicates significant difference in
phosphorylation (P < 0.05) for comparison of control samples to ischemia-reperfusion samples
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active EGFR, INSR and ROR2 together. ROR1 and
RYK, demonstrating downregulation of phosphoryl-
ation by ischemia-reperfusion, were grouped together
in the other end of the heatmap (Fig. 2b).
ROR1 is expressed in healthy and ischemic pig heart
As ROR1 was one of the most significantly regulated RTKs
in the human heart expression analysis (Fig. 1b), and signifi-
cantly downregulated in the ischemic pig heart (Fig. 2), it
was selected for further validation. To confirm the presence
of ROR1 in the heart in vivo, lysates from pig myocardium
were analyzed by Western blotting with a polyclonal
anti-ROR1 antibody. A band of the predicted size for
full-length ROR1 protein (130 kDa) was detected in both
control and ischemia-reperfusion-injured samples (Fig. 3a
and b). The expression of ROR1 mRNA was confirmed
by RT-PCR (Fig. 3c). In both analyses, ROR1 expres-
sion did not demonstrate statistically significant differ-
ence between control and ischemia-reperfusion
samples.
ROR1 expression and phosphorylation are downregulated
by hypoxia-reoxygenation in cardiomyocytes in vitro
Analyses of the samples available from the IST Online
database (Fig. 1) and the pig in vivo model (Figs. 2 and 3)
indicated the presence of ROR1 in the heart tissue after is-
chemia and reperfusion, but did not allow for temporal
analyses of ROR1 expression or activity at different time
points after hypoxia and reoxygenation. To address the
ROR1 regulation in vitro in cardiomyocytes under condi-
tions simulating ischemia-reperfusion, HL-1 mouse atrial
cardiomyocytes and H9c2 rat cardiomyoblasts were ex-
posed to hypoxia (1% O2) in a hypoxic workstation for 1,
3 or 24 h. Cells were subsequently either returned to nor-
moxia for 3 or 24 h (hypoxia-reoxygenation), or directly
lysed for expression analysis (hypoxia alone). ROR1 pro-
tein expression was analyzed by Western blotting.
In HL-1 cells, the total ROR1 protein level was signifi-
cantly reduced by 1 h treatment in hypoxia (P = 0.014),
remained low 3 h after reoxygenation, and was recov-
ered with a high variation in expression after 24 h of re-
oxygenation (Fig. 4a and b). Treatment for 3 h in
hypoxia also initially slightly reduced ROR1 protein ex-
pression, but the expression recovered already 3 h after re-
oxygenation (Fig. 4a and b). The longest time point of
hypoxia analyzed, 24 h, did not result in changes in ROR1
protein levels (Fig. 4a and b). In H9c2 cells, downregula-
tion of ROR1 was similarly observed in response to treat-
ment for 1 h in hypoxia (P = 0.002), followed by a trend of
expression returning back to the level of control samples
after reoxygenation (Fig. 4c and d). In contrast to ROR1,
ROR2 expression was not significantly regulated by
hypoxia-reoxygenation (Additional file 5 A and B).
To address whether ROR1 phosphorylation was regulated
in response to hypoxia, ROR1 was immunoprecipitated from
HL-1 cell lysates followed by anti-phosphotyrosine Western
A
B C
Fig. 3 ROR1 expression in adult pig heart. a Western analysis of ROR1 expression in pig heart samples. An approximately 130 kDa band,
corresponding to the predicted size of ROR1, was detected. b Densitometric quantification of ROR1 protein level relative to α-tubulin. c ROR1
mRNA expression relative to GAPDH mRNA expression in pig heart samples was measured by real-time RT-PCR. In B and C, values for individual
samples (n = 3 for control, n = 4 for ischemia-reperfusion) are plotted. Medians are indicated with horizontal lines
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analysis. The samples were collected at two time points: after
one hour of hypoxia, a time point that demonstrated signifi-
cant downregulation of total ROR1 protein level in both
HL-1 and H9c2 cells (Fig. 4), and after one hour of hypoxia
followed by 24 h of reoxygenation, a schedule chosen to re-
flect the ischemia-reperfusion treatment used for the in vivo
analysis (Fig. 2). ROR1 phosphorylation was downregulated
in response to both treatments (Additional file 6), suggesting
that hypoxia alone is sufficient for the observed effect.
ROR1 knockdown increases the viability of
cardiomyocytes in vitro
The regulation of ROR1 expression in both ischemia-re-
perfusion and hypoxia-reoxygenation models indicated
functional relevance for ROR1 activity in the hypoxic
heart. To address the contribution of ROR1 for the car-
diomyocyte viability, expression of the receptor was
knocked down in HL-1 cells by RNA interference, and the
relative amount of viable cells was measured by MTTassay.
Two ROR1-targeting siRNAs significantly enhanced the
cellular viability both in normoxia (P = 0.004 and P < 0.001
for siRNAs #1 and #2, respectively; n = 18) and after 24 h of
hypoxia followed by 24 h of reoxygenation (P = 0.003 and
P = 0.001 for siRNAs #1 and #2, respectively; n = 18), when
compared to negative control siRNAs (Fig. 5a and
Additional file 5 E). Consistent with the expression data,
knockdown of ROR2 expression did not significantly affect
HL-1 cell viability (Additional file 5 C-E), suggesting that
the effect was specific for ROR1 within the ROR subfamily
of RTKs.
ROR1 promotes phosphorylation of Akt and p38
To study the downstream signaling effects of ROR1
knockdown, phosphorylation status of Akt and p38 was
studied by Western blotting, as these pathways have
been shown to be involved in ROR1 signaling [25, 26].
Phosphorylation of both Akt and p38 was decreased in
HL-1 cells 24 h after siRNA transfection (Fig. 5b).
Wnt-5a is an activating ligand of ROR1 [27, 28] in
addition to other receptor such as ROR2 [27–29], RYK
[30] and Frizzled receptors [31]. Stimulation of HL-1
cells for 96 h with 200 or 400 ng/ml Wnt-5a signifi-
cantly reduced the viability of the cells in both
normoxia (P = 0.012 and P = 0.015, for 200 and
400 ng/ml, respectively; n= 9) and after 48-h hypoxia
followed by 24 h of reoxygenation (P= 0.006 and P < 0.001,
for 200 and 400 ng/ml, respectively; n = 9), as compared to
non-treated controls (Fig. 5c). In accordance with the de-
crease in the level of phosphorylated Akt and p38 by
ROR1-targeted RNA interference, phosphorylation of both
Akt and p38 was enhanced in response to treatment with
400 ng/ml of Wnt-5a for 30 min (Fig. 5d).
Taken together, these results indicate that ROR1 ex-
pression and activity suppress cardiomyocyte viability






Fig. 4 ROR1 protein level is regulated in cardiomyocytes in response
to hypoxia and reoxygenation. a A representative Western analysis
of ROR1 protein level in HL-1 cardiomyocytes after treatment with
hypoxia and reoxygenation. Cells were allowed to adhere for 24 h
after plating in normoxia. This was followed by culturing the cells in
a hypoxic work station at 1% O2 (hypoxia) and subsequently again
in the regular cell incubator in normoxia (reoxygenation) for the
indicated periods of time. As time points were distributed over three
days after plating, control samples cultured in normoxia for 24, 48 or
72 h were also analyzed. Time points (hypoxia+reoxygenation) 1 + 0,
1 + 3, 3 + 0 and 3 + 3 are comparable to the 24 h control (lane 10),
time points 1 + 24, 3 + 24, 24 + 0 and 24 + 3 to the 48 h control
(lane 11), and time points 24 + 24 to the 72 h control (lane 12). b A
box plot presentation of quantitation of ROR1 bands from three
Western blots similar to the one shown in panel A. ROR1 band
intensities were normalized to each sample’s actin level, and
subsequently divided by the control sample value of the respective
timepoint. c A representative Western analysis of ROR1 protein levels
in H9c2 cardiomyoblasts after treatment with hypoxia and
reoxygenation. Experiment was carried out as shown for HL-1 cells
in panel A. The antibody recognized two bands between 130 and
180 kDa, that both were down-regulated by ROR1 siRNA knockdown
(data not shown). d A box plot presentation of quantitation of ROR1
bands from three Western blots similar to the one shown in panel C.
Data were normalized as for panel B. Asterisk indicates significant
difference in expression
(P < 0.05) as compared to control samples
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Discussion
To address the potential of RTKs as therapeutic targets
in myocardial ischemia, expression and phosphorylation
of RTKs was systematically analyzed in human and por-
cine ischemic heart samples. A subgroup of RTKs, both
present in phosphorylated form in the ischemic myocar-
dium, and differentially regulated at the expression level
between the ischemic and normoxic samples, was identi-
fied. This subgroup included ALK, AXL, EGFR, EPHB2,
ERBB2, FGFR2, KIT, ROR1, ROR2 and TIE1. As the role
of ROR1 in ischemic heart has not previously been ad-
dressed, it was selected for further analyses. ROR1
expression and phosphorylation were found to be down-
regulated in cardiomyocytes in response to hypoxia.
Moreover, functional in vitro experiments with RNA
interference and Wnt-5a stimulation indicated that tar-
geting of ROR1 enhances cardiomyocyte viability.
Analysis of RTK expression in the acute myocardial in-
farction samples revealed 4 RTKs with significantly re-
duced expression (EGFR, ERBB2, ERBB3 and EPHA2)
when compared to healthy heart. Of these, ERBB2 has
also previously been shown to be downregulated in hyp-
oxic human heart [8]. While the other two ERBB family




Fig. 5 ROR1 knockdown reduces but Wnt-5a ligand treatment increases cardiomyocyte viability under normoxia and hypoxia-reoxygenation. a
HL-1 cells were transfected with two different siRNAs targeting ROR1 (ROR1 siRNA #1 and #2) or negative control siRNA. Twenty-four hours after
transfection, cells were either transferred into a hypoxic work station (1% O2) or were maintained in normoxia as controls. After another 24 h, all
cells were returned to normoxia for 24 h to allow for reoxygenation. Cell viability was analyzed using the MTT assay. A box plot presentation is
shown indicating cell viability as normalized to negative control siRNA-treated cells cultured in normoxia. The efficacy of the ROR1 siRNAs in
down-regulating ROR1 expression is indicated (ROR1 protein %). Three independent experiments each including six replicates were carried out. b
Western analysis of total and phosphorylated Akt and p38 in HL-1 cells lysed 48 h after siRNA transfection. c HL-1 cells were treated with the
indicated concentrations of Wnt-5a since plating. Twenty-four hours after plating, cells were either transferred into a hypoxic work station (1% O2)
or were maintained in normoxia as controls. After another 48 h, all cells were returned to normoxia for 24 h to allow for reoxygenation. Cell
viability was analyzed using the MTT assay. A box plot presentation is shown indicating cell viability as normalized to cells cultured in the
absence of the ligand in normoxia. Three independent experiments each including three replicates were carried out. d Western analysis of total
and phosphorylated Akt and p38 in HL-1 cells treated or not with 400 ng/ml of Wnt-5a for 30 or 60 min. Negative control cells were lysed at the
same time as the 30-min sample
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our analyses, the previous report by Munk et al. [8] indi-
cates upregulation of EGFR and no change for ERBB3
expression in hypoxia. Interestingly, EPHA2 has been
shown to have cardioprotective potential in mouse
models of myocardial ischemia and ischemic cardiomy-
opathy [32, 33].
Analysis of RTK expression in the ischemic cardiomy-
opathy samples revealed 3 RTKs with significantly en-
hanced expression (ROR1, KIT and TIE1) and 11 with
significantly reduced expression (EPHA2, LTK, PDGFRB,
ERBB3, FGFR2, AXL, ALK, ROR2, EPHA8, EPHB2 and
EPHB4) when compared to healthy heart. ROR1 expres-
sion was most significantly upregulated. However, the
roles for most RTKs identified in our analyses in ische-
mic cardiomyopathy remain to be elucidated in future
studies.
The phosphoarray analysis of porcine myocardial sam-
ples indicated the highest phosphorylation level for
EGFR, ROR2, INSR, EPHB3, EPHB2, TEK, RYK, ROR1
and EPHB6. For ROR1 and VEGFR2, difference in phos-
phorylation between control and ischemia-reperfusion
samples was statistically significant. While details about
the antibodies included in the phospho-RTK array are
not publicly available, the kit has been designed to detect
human receptors. A conservation analysis between the
human and porcine RTK protein sequences indicated
high conservation for most receptors (median global
similarity = 93.1%) and global similarity of 92.4% for
ROR1 (Additional file 7). However, the specificity of the
antibodies in the array could not be directly controlled
and, especially, the phosphorylation status of ROR1 in
ischemic heart remains to be studied in future analyses.
Nevertheless, a reproducible set of active RTKs in the is-
chemic heart was detected, including both novel recep-
tors (e.g. ROR1, ROR2) and ones formerly known to be
active in the heart (EGFR, ERBB2, INSR, VEGFR2).
Both ROR1 expression and phosphorylation were found
to be down-regulated in cardiomyocytes in vitro. Although
ROR1 phosphorylation was downregulated also in the pig
model of acute ischemia-reperfusion injury in vivo, ROR1
expression in the pig model demonstrated a nonsignificant
trend for increase. Moreover, ROR1 mRNA expression was
upregulated in the ischemic cardiomyopathy samples.
These findings could reflect the intrinsic differences in
measuring protein phosphorylation vs. expression, and the
associated feed-back regulation, but also the duration of
hypoxia in the different models. For example, ischemic car-
diomyopathy is a chronic ischemic disease involving heart
failure, while the ischemia-reperfusion-model in the pig
and the in vitro analyses are models for more acute hypoxic
conditions.
ROR1 signaling was demonstrated to inhibit cardio-
myocyte survival, as its knockdown increased, while its
ligand activation decreased, cellular viability. ROR1 and
ROR2 comprise the Receptor tyrosine kinase-like Or-
phan Receptor (ROR) family. While ROR signaling in
the ischemic heart has not previously been addressed,
both receptors are known to regulate heart development
during mouse embryogenesis [6, 7, 34]. Interestingly, in
our in vitro analyses, hypoxia affected expression of
ROR1, but not of ROR2, and knockdown of ROR1, but
not of ROR2, enhanced cardiomyocyte viability, implying
that the two receptors have overlapping but not fully re-
dundant biological functions in these cells. The pathways
regulating ROR1 functions in cardiomyocytes may in-
volve p38, as our phospho-Western analyses indicated
p38 regulation both in response to ROR1 knockdown as
well as to Wnt-5a ligand stimulation. Indeed, inhibition
of p38 signaling has been shown to enable adult cardio-
myocyte proliferation [35] and promote cardiac regener-
ation [36]. Interestingly, a ROR1-targeting monoclonal
antibody, cirmtuzumab, has been developed for the
treatment of chronic lymphatic leukemia [37] allowing
future analysis of its effect on normal and ischemic
heart.
Conclusions
In conclusion, we describe an RTK-proteome level ap-
proach to characterize RTK expression and activity in the
ischemic heart. ROR1 was identified as one of the RTKs
that was both present in the ischemic heart in an active
form and regulated in expression in a manner that associ-
ated with clinical and experimental ischemia. Manipula-
tion of ROR1 expression and activity in vitro indicated a
functional role for ROR1 in suppressing cardiomyocyte
viability. These findings warrant further studies addressing
the targeting of ROR1 as an approach to treat ischemic
heart disease.
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knockdown on cellular viability. HL-1 cells were transfected with two
different siRNAs targeting ROR2 (ROR2 siRNA #1 and #2) or negative control
siRNA. Twenty-four hours after transfection, cells were either transferred into
a hypoxic work station (1% O2) or were maintained in normoxia as controls.
After another 24 h, all cells were returned to normoxia for 24 h to allow for
reoxygenation. Cell viability was analyzed using the MTT assay. A box plot
presentation is shown indicating cell viability as normalized to negative
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experiments each including six replicates were carried out. D) Western
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